BioSpace News Archive

BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

EGF Theramed Health Corp. (CSE:TMED)(OTCQB:EVAHF)(FSE:AUHP) (the “Company”) is pleased to announce that the Company has entered into a letter of intent dated as of December 14, 2020 to acquire all of the issued and outstanding shares of Seedadelic Med Corp. (“Seedadelic”), a private Ontario corporation) in exchange for the issuance of 15,000,000 common shares of the Company at a deemed price of $0.115 per common share to Seedadelic shareholders

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increase

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the closing of its previously announced upsized underwritten public offering of 5,339,286 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 696,428 shares, at the

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced its financial results for the second fiscal quarter ended October 31, 2020. Second Quarter and Recent Highlights:

Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, today announced the launch, subject to market conditions, of an underwritten public offering of $100 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis. In connection with the offering, Cellecti

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Mon

Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell $125,000,000 of shares of its common stock. In connection with the offering, Castle expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock. All of the shares in the proposed offe

First individual enrolled in Phase 2b/3 study to assess efficacy and safety of CVnCoV. Study expected to enroll more than 35,000 participants, focusing on Europe and Latin America

Atlanta Oral & Facial Surgery and Bay Area Oral Surgery Management, both well-respected and nationally recognized oral surgery groups, announced that they have entered into a strategic partnership with Blue Sea Capital, a leading growth-oriented private equity firm, to form Beacon Oral Specialists and to position AOFS and BAOSM for continued expansion.